HC Staffing Firm Posts Triple-Digit Revenue Gains in Q421
Source: Streetwise Reports  (2/19/22)
Shares of a health care professional staffing and services company traded 12% higher after the company reported Q4/21 financial results that included a 116% YoY increase in revenue and a 1,149% YoY increase in net income. More >

Cannabis Cos. Expected to Post Better Revenues As of Q2/22
Source: Streetwise Reports  (2/18/22)
Whereas U.S. multistate cannabis operators are expected to do well in 2022, federal legalization of cannabis would give a jolt to companies of all sizes, noted a ROTH Capital Partners report. More >

Pharma Co. Decreases BMI by 14.3% in Obesity Trial
Source: Streetwise Reports  (2/18/22)
Shares of this pharmaceutical company traded 16% higher after it reported positive interim data from its long-term extension study of a treatment for obesity and hyperphagia in patients with Bardet-Biedl Syndrome (BBS). More >

Dialysis Equip. Co. Posts Record FY21 Sales
Source: Streetwise Reports  (2/17/22)
Shares of a wireless mobile dialysis equipment maker traded 15% higher after the company reported FY/21 financial results highlighting a 105% YoY increase in revenue to $102.6 million. More >

Small-Cap Drug Co. Fights Clinicians' COVID Stress
Source: Streetwise Reports  (2/15/22)
In a recent interview with Streetwise Reports, Cybin Inc.'s General and IP Counsel Robert Mino explained the company's position at the forefront of mental health treatment via psychedelics. "This sector has the potential to improve the human condition on a massive scale." More >

Pain Mgt. Co. Makes $604M Bid for BioDelivery Sciences
  (2/14/22)
Shares of BioDelivery Sciences International Inc. traded 52% higher after the company reported that it agreed to be acquired by Collegium Pharmaceutical Inc. in an all-cash deal for $5.60 per share. More >

Canadian Hedge Fund CIO Talks Top 2022 Prospects
Source: Streetwise Reports  (2/9/22)
AlphaNorth Asset Management was recently recognized with multiple performance awards at the 2021 Alternative IQ Canadian Hedge Fund Awards. The AlphaNorth Partners Fund won first place for its five-year annualized return gaining 40.35% for the period. The fund also placed second for its three-year return and third for its one-year return. Streetwise Reports sat down with CIO Steven Palmer to discuss some of the firm's recent investments and emerging opportunities for 2022. More >

Mental Health Co. Brings Psychedelics to the World
Source: Streetwise Reports  (2/9/22)
In Citi's Jan. 25, 2022 Psychedelic Call Series broadcast, Novamind CEO Yaron Conforti and Chief Medical Officer Dr. Reid Robison discussed how the company is increasing people's access to psychedelic therapies for mental health disorders. More >

Digital Medical Co.'s Earnings Are Just What the Doctor Ordered
Source: Streetwise Reports  (2/9/22)
Doximity Inc. shares traded 25% higher after the digital medical platform provider used by 80% of all physicians in the U.S. reported Q3/22 financial results that included a 67% YoY increase in revenue. More >

Todos COVID-19 Drug Shows Superiority to Remdesivir, Takes Dying Off the Table
Source: Vision and Value  (2/8/22)
In a phase 2 clinical study, Todos Medical's oral antiviral Tollovir showed a 100% reduction in mortality from COVID-19. More >

Investors: Will a Psychedelic Drug Take This Pharma Stock to the Next Level?
Source: Streetwise Reports  (2/7/22)
Algernon Pharmaceuticals plans to be the world's first company to test the psychedelic drug DMT in stroke patients, and it's close to achieving its goal. More >

Drug Re-Purposing Co. Pursues Novel Stroke Therapies
Source: Streetwise Reports  (2/3/22)
Drug re-purposing co. Algernon Pharmaceuticals Inc. is actively reinventing itself. The firm's leading therapeutic candidate NP-120 (Ifenprodil) is currently being evaluated in a Phase 2 trial for IPF and chronic cough, and the company is now moving forward with a revolutionary new use for DMT to treat ischemic stroke. More >

Co. Focused on Pipeline of Drug Candidates
  (1/31/22)
In the clinic, Algernon Pharmaceuticals is advancing Ifenprodil in three indications and DMT in stroke, noted a Research Capital Corp. report. More >

Biopharma Co. to Resubmit BLA to FDA for Type 1 Diabetes
Source: Streetwise Reports  (1/31/22)
Shares of Provention Bio Inc. traded 29% higher after the company reported that following its Type B meeting and conversations with the U.S. FDA, it is now planning to resubmit a Biologics License Application for delay of clinical type 1 diabetes in at-risk individuals. More >

Neuroscientist With Research Program Joins Biotech's SAB
Source: Streetwise Reports  (1/29/22)
ProMIS Neurosciences appointed to its science advisory board Canada-based Dr. Cheryl Wellington, professor, neuroscientist and head of a globally recognized neuro research program. More >

Pharma to Test if DMT Helps Brain Regain Function Post Stroke
Source: Streetwise Reports  (1/28/22)
During Streetwise Live! on Jan. 27, 2022, representatives of Algernon Pharmaceuticals discussed the use of the psychedelic DMT in stroke sufferers. On the broadcast were Algernon CEO Christopher Moreau and consultants to the firm, Dr. David Nutt and Dr. Rick Strassman. More >

Co. Meets Goals in COVID Drug Trial
Source: Streetwise Reports  (1/28/22)
Todos Medical has closed a Phase 2 trial of its antiviral 3CL protease inhibitor Tollovir after getting positive interim data. More >

FDA Approves First Tubeless Insulin Delivery Device
Source: Streetwise Reports  (1/28/22)
Shares of Insulet Corp. traded 15% higher after the company reported its Omnipod® 5 automated insulin delivery system has received clearance from the U.S. FDA. The Omnipod® 5 is the first tubeless system to be monitored and controlled remotely using a smartphone. More >

Read Why These 3 Institutions Like This Water Tech Co.
Source: Streetwise Reports  (1/26/22)
Forward Water Technologies Corp. is exploring applications for its forward osmosis water technology in the lithium extraction industry. More >

Possible Treatment for CRC Shows Promise
  (1/25/22)
New trial results of Exelixis' cabozantinib in colorectal cancer are encouraging for further development of the biopharma's XL902 in the indication, noted an H.C. Wainwright & Co. report. More >

Co. Looks to New Structures of Psychedelic Drug for Strokes
Source: Streetwise Reports  (1/25/22)
Algernon Pharmaceuticals Inc. has included novel salt forms of a psychedelic drug being investigated to combat strokes in its intellectual property applications. More >

Bone Cancer Drug Meets Goals, Stocks Rise
Source: Streetwise Reports  (1/25/22)
Shares of Sierra Oncology Inc. traded 48% higher after the company reported that topline data obtained during its Pivotal Phase 3 MOMENTUM Myelofibrosis Study showed that its momelotinib produced statistically significant improvements in anemia and splenic size. More >

FDA Gives Fast Track Status to Firm for Adrenal Rescue Pen
  (1/24/22)
Now with fast track status and positive Phase 1 study results, Antares Pharma plans to advance its ATRS-1902 product candidate into a second trial in Q2/22, noted a Ladenburg Thalmann report. More >

Fourth COVID-19 Vaccine Shot Shown Less Effective
  (1/24/22)
BioNTech aims to develop a COVID-19 vaccine targeting the Omicron variant, noted an H.C. Wainwright & Co. report. More >

‘Strong Data’ Expected From Todos Medical Data Lock
Source: Vision and Value  (1/24/22)
Todos Medical is set to take on the dominant players in oral antivirals for mild to moderate COVID-19, Pfizer Inc. and Merck & Co. Inc., with "strong data" expected to be released soon for its drug Tollovir. More >